|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2600116342 |
|
最近更新日期: Date of Last Refreshed on: |
2026-01-08 11:46:04 |
|
注册时间: Date of Registration: |
2026-01-08 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
富含透明质酸移植液在PGT-A患者整倍体单囊胚移植中的应用:一项单中心随机对照试验 |
|
Public title: |
Application of Hyaluronic acid-enriched transfer media in single euploid blastocyst transfer of PGT-A patients: a single center randomized controlled trial |
|
注册题目简写: |
整倍体胚胎胶 |
|
English Acronym: |
EuploidGlue |
|
研究课题的正式科学名称: |
富含透明质酸移植液在PGT-A患者整倍体单囊胚移植中的应用:一项单中心随机对照试验 |
|
Scientific title: |
Application of Hyaluronic acid-enriched transfer media in single euploid blastocyst transfer of PGT-A patients: a single center randomized controlled trial |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
吴兴武 |
研究负责人: |
赵琰 |
|
Applicant: |
Xingwu Wu |
Study leader: |
Yan Zhao |
|
申请注册联系人电话: Applicant telephone: |
+86 791 8631 0471 |
研究负责人电话: Study leader's telephone: |
+86 791 8631 0471 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
wuxingwujy@163.com |
研究负责人电子邮件: Study leader's E-mail: |
zhaoyan1972009@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
江西省南昌市西站大街508号 |
研究负责人通讯地址: |
江西省南昌市西站大街508号 |
|
Applicant address: |
No. 508, Xizhan Street, Nanchang City, Jiangxi Province |
Study leader's address: |
No. 508, Xizhan Street, Nanchang City, Jiangxi Province |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
江西省妇幼保健院 |
||
|
Applicant's institution: |
Jiangxi Maternal and Child Health Hospital |
||
|
研究负责人所在单位: |
江西省妇幼保健院 |
||
|
Affiliation of the Leader: |
Jiangxi Maternal and Child Health Hospital |
||
|
是否获伦理委员会批准: |
是/Yes |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
SZYX-202405; SZYX-202515 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
江西省妇幼保健院生殖医学伦理委员会 |
||
|
Name of the ethic committee: |
Reprocuctive Medicine Ethics Committee of Jiangxi Maternal and Child Health Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2024-12-25 00:00:00 |
||
|
伦理委员会联系人: |
刘佩佩 |
||
|
Contact Name of the ethic committee: |
Liu Peipei |
||
|
伦理委员会联系地址: |
江西省南昌市西站大街508号 |
||
|
Contact Address of the ethic committee: |
No. 508, Xizhan Street, Nanchang City, Jiangxi Province |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 188 7044 3673 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
1825163162@qq.com |
|
研究实施负责(组长)单位: |
江西省妇幼保健院 |
||||||||||||||||||||||
|
Primary sponsor: |
Jiangxi Maternal and Child Health Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
江西省南昌市西站大街508号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 508, Xizhan Street, Nanchang City, Jiangxi Province |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
江西省生殖医学临床重点专科建设项目提供经费支持。 |
||||||||||||||||||||||
|
Source(s) of funding: |
This study was funded by the Clinical Key Specialty Construction Project of Reproductive Medicine in Jiangxi Province. |
||||||||||||||||||||||
|
Target disease: |
infertility |
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
明确对于 PGT-A 的不孕患者的解冻整倍体单囊胚移植中,采用富含透明质酸移植液(胚胎胶)是否可以获得比常规移植液(G2)更高的活产率。 |
||||||||||||||||||||||
|
Objectives of Study: |
To determine whether using a hyaluronic acid-rich transfer medium (EmbryoGlue) can achieve higher live birth rates compared to conventional transfer medium (G2) in the frozen-thawed euploid blastocyst transfer for PGT-A infertility patients. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
1.年龄20-45 岁; 2.PGT-A 检测后移植 1 枚整倍体囊胚(评分>3BC 的 D5/D6 囊胚); 3.采用自然周期、改良自然周期、激素替代周期或降调节激素替代周期进行内膜准备。 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Age range: 20-45 years old; 2. After PGT-A testing, transfer one euploid blastocyst (D5/D6 blastocyst with a score>3BC); 3. Using natural cycles, modified natural cycles, hormone replacement cycles, or downregulated hormone replacement cycles for endometrial preparation. |
||||||||||||||||||||||
|
排除标准: |
1.有辅助生育技术禁忌症或妊娠禁忌症的患者; 2.PGT-M、PGT-SR 周期及染色体异常患者; 3.移植嵌合体胚胎或未诊断明确的胚胎; 4.供精或供卵周期; 5.先天子宫畸形、重度宫腔粘连、粘膜下子宫肌瘤、严重子宫腺肌症; 6.移植前内膜厚度小于 6mm; 7.参加其他临床研究的患者。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients with contraindications to assisted reproductive technology or pregnancy; 2. Patients with PGT-M, PGT-SR cycle and chromosomal abnormalities; 3. Transfer chimeric embryos or undiagnosed embryos; 4. Sperm or egg supply cycle; 5. Congenital uterine malformation, severe intrauterine adhesions, submucosal uterine fibroids, severe adenomyosis; 6. The thickness of the endometrium before transplantation is less than 6mm; 7. Patients participating in other clinical studies. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-02-01 00:00:00至 To 2027-12-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从From 2026-02-01 00:00:00 至 To 2027-12-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
女性 |
Gender: |
Female |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
研究开始前,由一位研究人员采用SAS统计软件中随机数发生器生成随机数,按1:1 分配至两组,该研究人员不参与后续受试者的招募及研究的实施过程。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Before the study begins, a researcher will use the random number generator in SAS statistical software to generate random numbers and allocate them to two groups at a 1:1 ratio. This researcher will not participate in the subsequent recruitment of subjects and the implementation of the study. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
单盲 |
|
Blinding: |
single-blinded |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
完成临床试验2年后将数据提交到中国临床试验注册中心网站。 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
After completing the clinical trial for 2 years, submit the data to the website of the China Clinical Trial Registration Center. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
数据采集在江西省妇幼保健院辅助生殖中心的病例系统中进行并由专人进行管理。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
Data collection was carried out in the case system of the Assisted Reproductive Center of Jiangxi Maternal and Child Health Hospital and managed by a dedicated person. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |